Skip to main content

Schering Expands Target Validation Collaboration with Atugen to Include RNAi

NEW YORK, June 17 - Schering has extended a collaboration with Atugen of Berlin to validate drug targets associated with cancer using Atugen's KnockDown technology.


The two companies have been collaborating for six years so far. The new agreement adds two more years to the partnership, and has been expanded to include Atugen's RNA interference technology. Atugen will develop its GeneBloc antisense molecules and/or siRNA molecules that are designed to inhibit expression of drug target candidates selected by Schering. Atugen will analyze the effects of the knockdown to validate gene function and disease association.


Under the terms of the new agreement, Atugen will receive annual licensing fees, research funding, and milestone payments.


Atugen will be working with Schering's research scientists in Germany and its Berlex Biosciences subsidiary in California.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.